SEC Form 4 · accession 0000899243-15-003968
Aegerion Pharmaceuticals, Inc. · AEGR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sandford D Smith
Officer — Chief Executive Officer · Director
Period of report
Aug 21, 2015
Accepted (ET)
Aug 25, 2015 · 4:22 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001338042
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F2 | $18.26 | Aug 21, 2015 | A | 40,000 | A | — | Aug 20, 2025 | Common Stock | 40,000 | 40,000 | D |
| Restricted Stock UnitsF3,F4 | — | Aug 21, 2015 | A | 13,333 | A | — | — | Common Stock | 13,333 | 13,333 | D |
Explanation of responses
- F1The stock option award has an exercise price equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant.
- F2Subject to the Reporting Person's continued employment with the Issuer, the shares of common stock underlying this stock option award will vest and become exercisable in full on January 27, 2016.
- F3Each restricted stock unit represents a contingent right to receive one share of common stock.
- F4Subject to the Reporting Person's continued employment with the Issuer, the restricted stock units will vest and become exercisable over three years, with 16.67% of the units vesting on January 27, 2016, and the remaining 83.3% of the grant vesting monthly in equal installments over the thirty-one months following January 27, 2016.